Qurient Co., Ltd. (KOSDAQ:115180)
13,150
-270 (-2.01%)
At close: Nov 17, 2026
Qurient Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 7,129 | 6,983 | 9,180 | 9,032 | 8,469 | 4,886 |
Revenue Growth | -13.85% | -23.94% | 1.64% | 6.65% | 73.33% | - |
Gross Profit Gross Profit Growth | 759.12 | 929.87 | 1,351 | 1,763 | 1,782 | 885.22 |
Operating Income Operating Income Growth | -36,735 | -29,757 | -27,478 | -23,213 | -27,475 | -24,243 |
Net Income Net Income Growth | -38,781 | -30,123 | -24,182 | -21,117 | -25,457 | -22,848 |
Earnings Per Share EPS Growth | -1046.05 | -880.12 | -812.45 | -1193.08 | -1623.09 | -1517.69 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Wholesale and Retail Pharmaceutical Wholesale and Retail Growth | 6,983 | 9,168 | 9,032 | 7,877 | 4,686 |
Pharmaceutical Research and Development Pharmaceutical Research and Development Growth | - | 11.54 | - | 591.72 | 200 |
Total Total Growth | 6,983 | 9,180 | 9,032 | 8,469 | 4,886 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 25,042 | 50,052 | 48,165 | 42,821 | 33,099 | 51,909 |
Total Debt Total Debt Growth | 14,761 | 12,652 | 841.34 | 333.7 | 807.48 | 874.01 |
Net Cash (Debt) Net Cash Growth | 10,281 | 37,399 | 47,324 | 42,487 | 32,291 | 51,035 |
Net Cash Growth | -72.65% | -20.97% | 11.38% | 31.57% | -36.73% | -11.36% |
Net Cash Per Share Net Cash Per Share Growth | 277.32 | 1092.71 | 1589.96 | 2400.31 | 2058.81 | 3389.98 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -37,143 | -28,673 | -23,316 | -21,970 | -25,003 | -24,372 |
Capital Expenditures CapEx Growth | -24.94 | -59.89 | -19.33 | - | -12.85 | -146.64 |
Free Cash Flow Free Cash Flow Growth | -37,168 | -28,733 | -23,336 | -21,970 | -25,016 | -24,519 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 10.65% | 13.32% | 14.71% | 19.52% | 21.04% | 18.12% |
Operating Margin | -515.27% | -426.16% | -299.33% | -257.02% | -324.43% | -496.18% |
Pretax Margin | -565.30% | -447.71% | -272.30% | -246.34% | -320.22% | -488.83% |
Profit Margin | -543.97% | -431.40% | -263.42% | -233.80% | -300.61% | -467.63% |
FCF Margin | -521.36% | -411.50% | -254.21% | -243.25% | -295.40% | -501.83% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 76.63 | 169.76 | 16.67 | 10.00 | 14.18 | 67.88 |